H.C. Wainwright Downgrades Vertex Pharmaceuticals To Neutral, Lowers PT to $85
In a research report issued today, Vertex Pharmaceuticals (VRTX) was downgraded by analyst Andrew Fein at H.C. Wainwright from “Buy” to “Hold”. The analyst also lowered his price target on shares of Vertex to $85 (from $105) as he believes that current trading levels reflect appropriate value for the shares.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Andrew Fein currently has a one-year average return of 10.6% and a 71% success rate. Fein has a 36.1% average profit recommending VRTX, and he is ranked #979 out of 3128 analysts.